The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution agreement for Genesis products

16 Jul 2009 07:00

RNS Number : 7478V
Omega Diagnostics Group PLC
16 July 2009
 



AIM: ODX

Omega Diagnostics Group PLC ('Omega')

UK Distribution agreement for Genesis products 

Omega, the AIM listed medical diagnostics company, announces that its UK-based subsidiary, Genesis Diagnostics Ltd ('Genesis') has signed an exclusive distribution agreement with Biohit Healthcare Ltd ('Biohit'), the UK-based subsidiary of Biohit Oyj, a Finnish public company which develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Biohit will take on the UK distribution and servicing of the Genesis product range using their UK-wide sales force and will offer complete coverage of the UK NHS hospital network. Both companies are committed to maintaining and improving upon the high level of customer service provided by Genesis. Biohit already services many current Genesis customers and the customer base is expected to expand as a result of this agreement.

Andrew Shepherd, Chief Executive of Omega, said, "The synergy between Genesis and Biohit is clear in that both companies service the same clinical laboratory market with complementary products. The UK market for clinical diagnostic products is highly competitive and we need to have a full scale sales force that can operate across the UK and increase our business base going forward. Using Biohit provides us with access to a much enlarged customer base and allows our resources to be focussed on other growth areas in the UK and beyond."

 

Richard Vaughton, Managing Director of Biohit commented, "The addition of Genesis products enhances the offering to our current customer base and helps focus our sales drive in the clinical laboratory market. We look forward to providing an excellent service to existing Genesis customers, many of whom we are familiar with, and to winning many new customers."

Further enquiries:

Omega Diagnostics Group PLC:

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel : 020 7397 8900

Nick Wells, Andy Roberts, Elizabeth Bowman

ebowman@cenkos.com

Walbrook PR Limited

Tel : 020 7933 8787

Paul McManus

Mob : 07980 541 893

paul.mcmanus@walbrookpr.com

Information on Biohit Oyj

Biohit Oyj, a Finnish Public company, develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Established in 1988, Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in FranceGermany, the UKRussiaChinaJapan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit Oyj had net sales of 35.1M euros in 2008 and employed 370 personnel. 

Geographically sales are split as follows: Europe: 55.6%North & South America 18.1%Asia 11.5%Other Countries 14.8%

Biohit's shares (BIOBV) are quoted on NASDAQ OMX Helsinki. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDRBBBGGCU
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.